This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial / Tempero, Margaret A; Pelzer, Uwe; O'Reilly, Eileen M; Winter, Jordan; Oh, Do-Youn; Li, Chung-Pin; Tortora, Giampaolo; Chang, Heung-Moon; Lopez, Charles D; Bekaii-Saab, Tanios; Ko, Andrew H; Santoro, Armando; Park, Joon Oh; Noel, Marcus S; Frassineti, Giovanni Luca; Shan, Yan-Shen; Dean, Andrew; Riess, Hanno; Van Cutsem, Eric; Berlin, Jordan; Philip, Philip; Moore, Malcolm; Goldstein, David; Tabernero, Josep; Li, Mingyu; Ferrara, Stefano; Le Bruchec, Yvan; Zhang, George; Lu, Brian; Biankin, Andrew V; Reni, Michele. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 41:11(2023), pp. 2007-2019. [10.1200/JCO.22.01134]

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Reni, Michele
Ultimo
2023-01-01

Abstract

This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).
File in questo prodotto:
File Dimensione Formato  
Tempero_APACT_primary_JCO.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 4.57 MB
Formato Adobe PDF
4.57 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/134899
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 46
social impact